Introduction: Colon cancer in pregnancy is uncommon. Only a small number of case reports have been published in the literature on the use of chemotherapeutic drugs during pregnancy. Reports of such cases assist clinicians in further investigating the use of chemotherapy in pregnancy.
Case Presentation: FOLFOX-6 was administered to a pregnant, 33-year-old Saudi woman with metastatic colon cancer from 22 to 30 weeks of gestation. Her cancer was diagnosed during her pregnancy. She tolerated the chemotherapy well and delivered a full-term baby girl with no obvious harm, and normal development was documented at her 2-year follow-up examination.
Conclusion: Colon cancer during pregnancy is not easily detected and is difficult to manage. A detailed history and high clinical suspicion are needed in patients who present with symptoms and signs suggestive of malignancy. A multidisciplinary approach with patient involvement is needed to decrease morbidity and mortality caused by both treatment and the cancer in the mother and to limit side effects for the fetus. Further data and long-term follow-up are needed to better understand the potential long-term side effects of chemotherapeutic drugs on offspring.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469397 | PMC |
| http://dx.doi.org/10.1186/s13256-015-0621-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Automatic Quality Control System and Adenoma Detection Rates During Routine Colonoscopy: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Importance: High-quality colonoscopy reduces the risks of colorectal cancer by increasing the adenoma detection rate. Routine use of an automatic quality control system (AQCS) to assist in colorectal adenoma detection should be considered.
Objective: To evaluate the effect of an AQCS on the adenoma detection rate among colonoscopists who were moderate- and low-level detectors during routine colonoscopy.
Vulvar Carcinoma in Pregnancy: A Case Report on Diagnosis, Management, and Surgical Outcomes.
Cureus
December 2024
Obstetrics and Gynaecology, Fernandez hospital, Hyderabad, IND.
Vulvar cancer is an uncommon malignancy in reproductive-aged women, and its occurrence during pregnancy is rare. This report presents a case of vulvar squamous cell carcinoma (VSCC) diagnosed perioperatively in a 35-year-old pregnant woman. The patient was incidentally found to have lichen sclerosis and a suspicious vulvar lesion during an emergency cesarean section.
View Article and Find Full Text PDFHealth system financing fragmentation and maternal mortality transition in Mexico, 2000-2022.
Int J Equity Health
January 2025
Center for Health Systems Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
Objective: To analyze the temporal and territorial relationship between health system financing fragmentation and maternal mortality in the last two decades in Mexico.
Methods: We conducted an ecological-longitudinal study of the maternal mortality ratio (MMR) in the 32 states of Mexico during the period 2000-2022. Annual MMRs were estimated at the national and state levels according to health insurance.
Mental Health Aspects of Genetic Screening and Testing in Obstetrics and Gynecology.
Obstet Gynecol Clin North Am
March 2025
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, UC Davis Health, Sacramento, CA, USA. Electronic address:
Availability of genetic testing and screening options has advanced significantly, and increasingly becoming included in obstetric (OB) and gynecologic practices. Advanced technologies have caused genetic screening to become more complex. Genetic screening is recommended for all pregnant patients and is routinely offered in OBs and gynecology.
View Article and Find Full Text PDFMucinous ovarian carcinoma: Impact of ovarian stimulation, hormonal contraception, and hormone replacement therapy.
Eur J Obstet Gynecol Reprod Biol
January 2025
Département de chirurgie, centre Léon Bérard, Lyon, France; INSERM U1290 RESHAPE, France; Hôpital Femme Mère Enfant, Bron, France. Electronic address:
Unlike high-grade serous carcinoma (HGSC), which mainly affects postmenopausal women, mucinous ovarian carcinoma (MOC) affects younger patients, with a median age at diagnosis of 53 years, and is rare among premenopausal women. After they receive anticancer treatment, these women encounter specific issues involving fertility preservation (FP) and/or pregnancy, which potentially require assisted reproductive technology (ART) as well as the prescription of hormonal contraception (HC) or hormone replacement therapy (HRT). We reviewed the available literature in PubMed/Medline concerning the risks of the development of ovarian cancer (OC), including MOC, associated with ART, HC and HRT, and literature on the impact of ovarian stimulation in the context of FP and/or ART, HC and HRT in women previously treated for OC, including MOC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!